Tests ACI-24.060 in early Alzheimer's disease and adults with Down syndrome
Tests ACI-24.060 safety in early Alzheimer's and in adults with Down syndrome.
Key facts
- Who runs it
- AC Immune SA
- Where
- Cambridge, Liverpool, London, Oxford, and Warrington, United KingdomSee the 6 sitesAlso in 2 other countries, 20 sites
- Registry title
- A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 304 people, planned
- Started
- 21 Jun 2022
- Expected to end
- Apr 2029
- Type of study
- Interventional, 11 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebo (Study Part 1a)
- ACI-24.060 at Dose A in Study Part 1a
- ACI-24.060 at Dose B in Study Part 1a
- ACI-24.060 at Dose C in Study Part 1a
- ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b
- Placebo (Study Part 2)
- ACI-24.060 at Dose A in Study Part 2
- ACI-24.060 at Dose B in Study Part 2
- ACI-24.060 at Dose C in Study Part 2
- Placebo (Study Part 1b)
- ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Record updated
- 10 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 85 with early (prodromal) Alzheimer's disease, and for adults aged 35 to 50 with Down syndrome and amyloid in the brain.
- Age
- Alzheimer's part: 50 to 85 years. Down syndrome part: 35 to 50 years (35 to 39 only with earlier proof of amyloid findings consistent with Alzheimer's disease).
- Sex
- Men and women can join.
- Disease stage
- Alzheimer's part: mild cognitive impairment due to Alzheimer's disease (prodromal Alzheimer's) with a Clinical Dementia Rating Global Score of 0.5. Down syndrome part: mild to moderate intellectual disability and no diagnosis of Alzheimer's dementia at randomization. Both parts need a PET scan showing amyloid.
- Earlier treatment
- People cannot have had ACI-24 or other active immunotherapy against Alzheimer's, unless there is firm evidence they only got placebo. Anti-Alzheimer's drugs (acetylcholinesterase inhibitor, memantine) must be at a stable dose for at least 2 months.
- Biomarker or test result
- A PET scan at screening must show amyloid. Down syndrome part: trisomy 21 or a complete unbalanced translocation of chromosome 21.
Main reasons for not taking part
- Positive HIV test, active hepatitis B or C, or active syphilis at screening
- Immune or autoimmune disorders, or recent immunosuppressant drugs
- Uncontrolled seizures, or significant psychiatric or neurological disorders
- MRI showing certain brain bleeds, swelling or strokes, or no MRI or PET scan possible
- Any vaccine within 4 weeks before randomization
The registry criteria, word for word
Show all 43 criteriaShow less
Who can take part
- Study Part 1a and Part 1b
- Age ≥50 and ≤85 years at screening
- Diagnosis of prodromal AD: MCI due to AD according to National Institute on Aging Alzheimer's Association (NIA-AA) criteria
- PET scan at screening consistent with the presence of amyloid pathology
- Clinical Dementia Rating (CDR)-Global Score of 0.5
- Subjects either not taking any marketed treatment for AD or receiving a stable dose of an acetylcholinesterase inhibitor (ACHEI) and/or memantine for at least 2 months prior to screening; Study Part 2
- Age ≥35 and ≤50 years at screening (subjects with DS with age ≥35 and ≤39 years may be considered on the condition that there is prior evidence of amyloid results compatible with AD pathology at PET-scan and/or in biofluids)
- Male or female subjects with DS with a cytogenetic diagnosis being either trisomy 21 or complete unbalanced translocation of chromosome 21
- PET scan at screening consistent with the presence of amyloid pathology
- Mild to moderate intellectual disability as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classification
- Subjects must have a study partner who has direct and regular contact, at least 10 hours per week, with the subject and who is able to provide reliable answers to questions related to the subject, according to the study investigator
Who cannot take part
- Concomitant or history of clinically significant and/or unstable psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks, hemorrhagic and/or non-hemorrhagic stroke). Subjects with a history of major depressive disorder may be included if they have been free of major episodes for at least 1 year before screening
- History of severe allergic reaction (eg, anaphylaxis) including, but not limited to severe allergic reaction to previous vaccines, foods, and/or medications
- MRI scan at screening showing a single area of cerebral vasogenic edema, superficial siderosis, or evidence of a previous macro-hemorrhage or showing more than 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"). Evidence of space occupying lesions other than benign meningioma of less than 1 cm diameter, more than 2 lacunar infarcts, or 1 single infarct larger than 1 cm in diameter. Screening MRI scan showing structural evidence of alternative pathology not consistent with AD and is considered to be at the origin of subject's symptoms
- MRI examination cannot be done for any reason, including but not limited to metal implants contraindicated for MRI and/or severe claustrophobia
- Previous treatment with ACI-24 or any other active immunotherapy against AD at any time in the past unless there is firm evidence that the subject received placebo only and the placebo formulation is not expected to induce any specific immune response
- Previous treatment with any investigational and/or marketed passive immunotherapy against AD within 6 months before screening or 5 half-lives, whichever is longer, unless there is firm evidence that the subject received placebo only
- Ongoing treatment with any approved anti-amyloid passive immunotherapy for Alzheimer's disease
- Use of acetylcholinesterase inhibitor or glutamatergic drugs (eg, memantine, topiramate, lamotrigine) if not on stable dose for at least 2 months before screening
- Any vaccine, either live or not, including but not limited to influenza or COVID-19 vaccine, received within 4 weeks before randomization
- Subjects undergoing lumbar puncture and being treated with any anticoagulants or antiplatelet drugs, except aspirin at doses of 100 mg daily or lower
- Use of antidepressants (other than selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors at stable dose); typical antipsychotics; γ-aminobutyric acid agonists (eg, gabapentin); or stimulants (eg, methylphenidate, modafinil). Stable doses of atypical antipsychotics or benzodiazepines are only allowed if this is not considered to influence the safety and the efficacy of the study treatment according to the site investigator and the sponsor medical monitor
- Current use of immunosuppressant or immunomodulating drugs or their use within the 6 months before study screening. Current use of oral steroids or their use within the 3 months before study screening; Additional Exclusion Criteria in Study Part 2; The following are exclusion criteria at the time of randomization but will not be considered as exclusionary after treatment assignment:
- DSM-5 criteria for substance use disorders drug or alcohol abuse or dependence (with the exception of tobacco use disorder) currently met within the past 5 years
- History or presence of uncontrolled seizures. If there is a history of seizures, they must be well controlled, with no occurrence of seizures in the 2 years before study screening. The use of antiepileptic medications is permitted
- History of meningitis or meningoencephalitis
- History of moderate or severe traumatic brain injury
- History or presence of inflammatory neurological disorders
- History or presence of immunological or autoimmune disorders
- Subjects with a positive Human Immunodeficiency Virus (HIV-1 and 2) test at screening
- Subjects with presence of antibody titers related to immunological or autoimmune disorders at screening
- Chronic use of opioid analgesics. A limited treatment duration for acute conditions until 24 hours before cognitive assessment is allowed
- Clinical diagnosis of AD dementia in DS as per International Classification of Diseases 10 (ICD-10)
- Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of the study treatment (eg, moderate and/or severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator's judgement
- Subjects with clinical or laboratory evidence of active hepatitis B or C at screening (eg, HBV or HCV antigens)
- Subjects with treated hypothyroidism not on a stable dose of replacement medication for at least 2 months before screening and having clinically significant abnormal serum T4 and/or thyroid stimulating hormone at screening
- Significant risk of suicide, defined using the C-SSRS as the subject answering "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behavior within the past 12 months
- Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator
- Subjects with positive syphilis serology consistent with active syphilis at screening
- Any contraindication for PET scan imaging
- Any contraindication to lumbar puncture in subjects undergoing this procedure (note: lumbar puncture is optional in subjects with DS)
- DSQIID >20
- Intelligence quotient score <40 (KBIT-2)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 85 years old?
Where in United Kingdom
Also in 2 other countries, 20 sites
- Cambridge and Peterborough NHS Foundation Trust - Windsor Research UnitsCambridge, United KingdomContact: Olivier Sol, MDNo longer taking part
- Liverpool University Hospitals NHS Foundation TrustLiverpool, United KingdomContact: Olivier Sol, MDTaking people
- Re:Cognition Health LimitedLondon, United KingdomContact: Olivier Sol, MDTaking people
- South London and Maudsley NHS Foundation Trust of The Maudsley HospitalLondon, United KingdomContact: Olivier Sol, MDTaking people
- Oxford Health NHS Foundation TrustOxford, United KingdomContact: Olivier Sol, MDTaking people
- NeuroClin LimitedWarrington, United KingdomContact: Olivier Sol, MDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
The 11 groups in the trial
- Placebo for Study Part 1a (Prodromal AD)Placebo, for comparison
Prodromal AD participants receive placebo at predefined time points over 48 weeks
Treatment: Placebo (Study Part 1a)
- ACI-24.060 at Dose A in Prodromal ADTreatment being tested
Prodromal AD participants receive dose A of ACI-24.060 at predefined time points over 48 weeks
Treatment: ACI-24.060 at Dose A in Study Part 1a
- ACI-24.060 at Dose B in Prodromal ADTreatment being tested
Prodromal AD participants receive dose B of ACI-24.060 at predefined time points over 48 weeks.
Treatment: ACI-24.060 at Dose B in Study Part 1a
- ACI-24.060 at Dose C in Prodromal ADTreatment being tested
Prodromal AD participants receive dose C of ACI-24.060 at predefined time points over 48 weeks.
Treatment: ACI-24.060 at Dose C in Study Part 1a
- ACI-24.060 with an additional adjuvant at Dose D in Prodromal ADTreatment being tested
Prodromal AD participants receive ACI-24.060 with an additional adjuvant at Dose D at predefined time points over 74 weeks.
Treatment: ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b
- Placebo for Study Part 2 (Down syndrome)Placebo, for comparison
Participants with Down syndrome receive placebo at predefined time points over 74 weeks
Treatment: Placebo (Study Part 2)
- ACI-24.060 at Dose A in Down syndromeTreatment being tested
Participants with Down syndrome receive dose A of ACI-24.060 at predefined time points over 74 weeks. Dose A will be a dose already tested in Study Part 1.
Treatment: ACI-24.060 at Dose A in Study Part 2
- ACI-24.060 at Dose B in Down syndromeTreatment being tested
Participants with Down syndrome may optionally receive a dose B of ACI-24.060 at predefined time points over 74 weeks.
Treatment: ACI-24.060 at Dose B in Study Part 2
- ACI-24.060 at Dose C in Down syndromeTreatment being tested
Participants with Down syndrome receive dose C of ACI-24.060 at predefined time points over 74 weeks. Dose C will be a dose already tested in Study Part 1.
Treatment: ACI-24.060 at Dose C in Study Part 2
- ACI-24.060 with an additional adjuvant at Dose E in Prodromal ADTreatment being tested
Prodromal AD participants receive ACI-24.060 with an additional adjuvant at Dose E at predefined time points over 74 weeks.
Treatment: ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Placebo for Study Part 1b (Prodromal AD)Placebo, for comparison
Prodromal AD participants receive placebo at predefined time points over 74 weeks
Treatment: Placebo (Study Part 1b)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)
- Plain-language title
- Tests ACI-24.060 in early Alzheimer's disease and adults with Down syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05462106, who can take part
- Record updated
- 10 July 2026